B-ALL
Clinical trials for B-ALL explained in plain language.
Never miss a new study
Get alerted when new B-ALL trials appear
Sign up with your email to follow new studies for B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Dual-Targeting CAR T-Cell therapy offers hope for relapsed childhood leukemia
Disease control Recruiting nowThis study tests a new treatment for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 an…
Matched conditions: B-ALL
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:19 UTC
-
New injection targets Hard-to-Treat leukemia in early trial
Disease control Recruiting nowThis early study tests a new drug called KSV01 in 30 adults whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will watch for side effects and see if the drug helps …
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
Radioactive drug boosts CAR T-Cell therapy in Tough-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B-ALL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
New CAR-T therapy offers hope for Tough-to-Treat leukemia in kids and young adults
Disease control Recruiting nowThis study tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with a type of blood cancer (B-ALL) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cells. The goal …
Matched conditions: B-ALL
Phase: PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
CAR-T cells take on donor infusion in battle against stubborn leukemia
Disease control Recruiting nowThis study tests whether a powerful immune cell therapy (CAR-T) works better than standard donor immune cells (DLI) to wipe out leftover leukemia in patients who had a stem cell transplant. About 70 people aged 3 to 80 with a certain type of leukemia and minimal residual disease …
Matched conditions: B-ALL
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Double CAR T-Cell attack aims to outsmart leukemia relapse
Disease control Recruiting nowThis study tests whether a second type of CAR T-cell therapy, targeting CD22, can keep acute lymphoblastic leukemia (ALL) from returning in people who already had CD19 CAR T-cell treatment. About 20 participants aged 3 to 65 who show no signs of cancer after their first CAR T-cel…
Matched conditions: B-ALL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Engineered immune cells take aim at childhood leukemias in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T-cell therapy for children and young adults (up to age 21) with certain blood cancers that have come back or not responded to standard treatment. The therapy uses the patient's own or a donor's immune cells, which are…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New study aims to predict leukemia relapse after CAR T-Cell therapy
Knowledge-focused Recruiting nowThis study looks at whether frequent blood and bone marrow tests can help doctors know if a child's leukemia will come back after CAR T-cell therapy. About 60 children and young adults aged 1 to 25 who have no signs of cancer after CAR T-cells will be followed for 2 years. The go…
Matched conditions: B-ALL
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC
-
New study tracks hidden side effects of CAR t therapy in kids
Knowledge-focused Recruiting nowThis study follows 100 children and young adults who have received CAR T-cell therapy to learn about short- and long-term side effects. Researchers will track how often patients get infections, have delays in blood cell recovery, or experience nerve damage. The goal is to better …
Matched conditions: B-ALL
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC